Výsledky vyhledávání - "Terasaki Mizuhiko"

Akademický článek

Development of the Japanese version of the Pediatric Quality of Life Inventory™ Brain Tumor Module

Autor: Terasaki Mizuhiko, Kumabe Toshihiro, Saito Nobuhito, Sugiyama Kazuhiko, Sawamura Yutaka, Ida Kohmei, Mukasa Akitake, Yanagisawa Takaaki, Higuchi Akiko, Sato Iori, Nishikawa Ryo, Ishida Yasushi, Kamibeppu Kiyoko

Publikováno v: Health and Quality of Life Outcomes, Vol 8, Iss 1, p 38 (2010)

Abstract Background The Pediatric Quality of Life Inventory™ (PedsQL™) is a widely-used modular instrument for measuring health-related quality of life in children aged 2 to 18 years. The PedsQL™ Brain Tumor Module is comprised of six scales: C

Externí odkaz: https://doaj.org/article/3dde077d028141c5a138cc2a1d84ae09

Zobrazit plný text záznamu

Akademický článek

Cancer-specific health-related quality of life in children with brain tumors

Autor: Sato, Iori, Higuchi, Akiko, Yanagisawa, Takaaki, Mukasa, Akitake, Ida, Kohmei, Sawamura, Yutaka, Sugiyama, Kazuhiko, Saito, Nobuhito, Kumabe, Toshihiro, Terasaki, Mizuhiko, Nishikawa, Ryo, Ishida, Yasushi, Kamibeppu, Kiyoko

Publikováno v: Quality of Life Research, 2014 May 01. 23(4), 1059-1068.

Externí odkaz: https://www.jstor.org/stable/24726409

Zobrazit plný text záznamu

Akademický článek

Factors influencing self- and parent-reporting health-related quality of life in children with brain tumors

Publikováno v: Quality of Life Research, 2013 Feb 01. 22(1), 185-201.

Externí odkaz: https://www.jstor.org/stable/24722680

Zobrazit plný text záznamu

Akademický článek

Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors

Autor: Terasaki, Mizuhiko, Bouffet, Eric, Katsuki, Hiroshi, Fukushima, Shintaro, Shigemori, Minoru

Publikováno v: In Surgical Neurology 2008 69(1):46-50

Zobrazit plný text záznamu

JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

Autor: Wakabayashi, Toshihiko, Natsume, Atsushi, Mizusawa, Junki, Katayama, Hiroshi, Fukuda, Haruhiko, Sumi, Minako, Nishikawa, Ryo, Narita, Yoshitaka, Muragaki, Yoshihiro, Maruyama, Takashi, Ito, Tamio, Beppu, Takaaki, Nakamura, Hideo, Kayama, Takamasa, Sato, Shinya, Nagane, Motoo, Mishima, Kazuhiko, Nakasu, Yoko, Kurisu, Kaoru, Yamasaki, Fumiyuki, Sugiyama, Kazuhiko, Onishi, Takanori, Iwadate, Yasuo, Terasaki, Mizuhiko, Kobayashi, Hiroyuki, Matsumura, Akira, Ishikawa, Eiichi, Sasaki, Hikaru, Mukasa, Akitake, Matsuo, Takayuki, Hirano, Hirofumi, Kumabe, Toshihiro, Shinoura, Nobusada, Hashimoto, Naoya, Aoki, Tomokazu, Asai, Akio, Abe, Tatsuya, Yoshino, Atsuo, Arakawa, Yoshiki, Asano, Kenichiro, Yoshimoto, Koji, Shibui, Soichiro, Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)

Publikováno v: Journal of neuro-oncology. 138(3):627-636

Purpose: This study explored the superiority of temozolomide (TMZ) + interferonβ (IFNβ) to standard TMZ as treatment for newly diagnosed glioblastoma (GBM) via randomized phase II screening design.
Experimental design: Eligibility criteria inc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=jairo_______::0266424cc470a11cd6a4a6a893e9700c
http://hdl.handle.net/2433/232946

Zobrazit plný text záznamu